The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 661-668

  Pepponi, Rita ^a   Marra, Giancarlo ^b   Fuggetta, Maria Pia ^c   Falcinelli, Sabrina ^a   Pagani, Elena ^a   Bonmassar, Enzo ^a   Jiricny, Josef ^b   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; CARMUSTINE; CISPLATIN; TEMOZOLOMIDE; DACARBAZINE; DNA ALKYLTRANSFERASE; DRUG DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TRANSFERASE;

ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DNA REPAIR; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MELANOMA; MELANOMA CELL; MISMATCH REPAIR; PRIORITY JOURNAL; PROGNOSIS; BASE MISPAIRING; CELL CLONE; CELL CULTURE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

ALKYL AND ARYL TRANSFERASES; BASE PAIR MISMATCH; CARMUSTINE; CISPLATIN; CLONE CELLS; DACARBAZINE; DNA LIGASES; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MELANOMA; TUMOR CELLS, CULTURED;

EID: 0037310904     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.043950     Document Type: Article

References (39)

1. Akiyama S, Chen ZS, Sumizawa T, and Furukawa T (1999) Resistance to cisplatin. Anticancer Drug Des 14:143-151.
2. Ali-Osman F (1989) Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res 49:5258-5261.
3. Allan JM, Engelward BP, Dreslin AJ, Wyatt MD, Tomasz M, and Samson LD (1998) Mammalian 3-methyladenine DNA glycosilase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Cancer Res 58:3965-3973.
4. Alvino E, Marra G, Pagani E, Falcinelli S, Pepponi R, Perrera C, Haider R, Castiglia D, Ferranti G, Bonmassar E, et al. (2002) High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Investig Dermatol 118:79-86.
5. Aquilina A, Ceccotti S, Martinelli S, Hampson R, and Bignami M (1998) CCNU sensitivity in mismatch repair defective human cells. Cancer Res 58:135-141.
6. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, and Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341.
7. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51:3367-3372.
8. 6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 3:837-847.
9. Dosch J, Christmann M, and Kaina B (1998) Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 19:567-573.
10. 6-Methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours. Br J Cancer 71:37-39.
11. Fink D, Aebi S, and Howel SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1-6.
12. Gerson BL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399.
13. Golub SH, Hanson DC, Sulit HL, Morton DL, Pellegrino MA, and Ferrone S (1976) Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. J Natl Cancer Inst 56:167-170.
14. Hansen MB, Nielsen SE, and Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210.
15. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, and Schadendorf D (2002) Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Investig Dermatol 118:923-932.
16. Helmbach H, Rossmann E, Kern MA, and Schadendorf D (2001) Drug-resistance in human melanoma. Int J Cancer 93:617-622.
17. Huncharek M, Caubet JF, and McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11:75-81.
18. Jiricny J and Nyström-Lahti M (2000) Mismatch repair defects in cancer. Curr Opin Genet Dev 10:157-161.
19. Jordan P and Carmo-Fonseca M (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229-1235.
20. Karran P (2001) Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22:1931-1937.
21. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, Zambruno G, and D'Atri S (2000) Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Investig Dermatol 115:1000-1007.
22. 6-alkylguanine DNA alkyltransferase in human liver and melanoma. Br J Cancer 66:355-360.
23. +/- lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci USA 98:7164-7169.
24. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166.
25. Modrich P (1997) Strand-specific mismatch repair in mammalian cells. J Biol Chem 272:24727-24730.
26. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119-6129.
27. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223.
28. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, and Czarnetzki BM (1994) Chemosensitivity testing of human melanoma cells: retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 73:103-108.
29. Serrone L and Hersey P (1999) The chemoresistance ofhuman malignant melanoma: an update. Melanoma Res 9:51-58.
30. 6-Alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1, 3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines. Oncology Res 4:241-248.
31. Smith MT, Evans CG, Doane-Setzer P, Castro VM, Tahir MK, and Mannervik B (1989) Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class μ glutathione transferase and its role in cellular resistance in rat brain tumour cells. Cancer Res 49:2621-2625.
32. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 9:1888-1895.
33. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52:249-258.
34. Thomas DC, Roberts JD, and Kunkel TA (1991) Heteroduplex repair in extracts of human HeLa cells. J Biol Chem 266:3744-3751.
35. 1-bis(2-chloroethyl)-N-nitrosourea (BCNU). Cancer Res 42:3102-3105.
36. 6-Alkylguanine-DNA alkyltransferase assays, in Cytotoxic Drug Resistance Mechanisms (Brown R and Boeger-Brown U eds) pp 167-178, Humana Press, Totowa, NJ.
37. 6-benzylguanine: a comparative study in vitro. Br J Cancer 73:482-490.
38. 6-alkylguanine-DNA alkyltransferase. Br J Cancer 74:1030-1036.
39. Wedge SR, Porteous JK, and Newlands ES (1997) Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40:266-272.